

Therapeutics Advisory Group Update - Issue 28 – February 2024

All recommendations discussed at the **February** TAG and D+TC meetings and ratified by the Planned Care and Medicines Management Working Group on behalf of the ICB – **February 2024**. Please share within your organisation as appropriate

Commissioning Summary

Commissioning Review - Off-label use of Testosterone in women for hypoactive sexual disorder during the menopause – guidance document update	<ul style="list-style-type: none"> Updated guidance document can be found on Netformulary
Commissioning Review - Dapagliflozin (Forxiga®) or Empagliflozin (Jardiance®) for treating heart failure – guidance document update	<ul style="list-style-type: none"> Updated guidance document can be found on Netformulary
Safety Update - MHRA Valproate alert update – work in progress	<ul style="list-style-type: none"> Work ongoing to manage risk to patients Pathway in development Commissioning agreements to be reviewed in due course Referral process to be confirmed
Formulary Application - Chloral hydrate 500mg/5ml oral solution for off-label use in treatment of dystonia	<ul style="list-style-type: none"> ADVICE - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation
Formulary application - Assicco (Glycopyrronium bromide) 1mg and 2mg tablets	<ul style="list-style-type: none"> New licensed tablet formulation of glycopyrronium Second line after Glycobromag for adults First line before Sialanar liquid for children
Formulary application - Tirzepatide for treating type 2 diabetes alongside diet and exercise in adults when it is insufficiently controlled – TA924	<ul style="list-style-type: none"> ADVICE - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation as per other GLP-1 options
Formulary application - Rimegepant for treating / preventing migraine	<ul style="list-style-type: none"> Red Hospital Only To confirm pathway before moving to primary care
Formulary application - Otigo (Phenazone 40mg/g, Lidocaine 10mg/g) Ear Drops	<ul style="list-style-type: none"> GREEN classification – suitable for prescribing in primary care Offer self-care and pain relief to all patients first
Formulary application - Phytomenadione (Vitamin K Nutritional Supplement) (NeoKay Oral Drops)	<ul style="list-style-type: none"> Red/Hospital Only. Hospital to supply full course
Local Guidance for information	
<ul style="list-style-type: none"> Primary Care Diagnosis & Management of Vitamin D Deficiency in Children – updated Jan 2024 MRSA Decolonisation regime – January 2024 PGD - Supply of oseltamivir for pre and post exposure of non-H7N9 avian influenza PGD - Supply of oseltamivir for pre and post exposure H7N9 avian influenza 	

Shared Care Updates

Agreed following minor amendments:

- Melatonin** for sleep disorders in children

Feedback from formulary and clinical groups

Meptazinol for pain relief	<ul style="list-style-type: none"> • BLACK – Not commissioned. No prescribing in primary or secondary care • No new patients. Existing patients can continue.
Asthma Primary Care Guidelines	<ul style="list-style-type: none"> • Updates supported by the TAG
Prescribing Guidance Update - Medicines to Prescribe by Brand Name in Primary Care	<ul style="list-style-type: none"> • Updates supported by the TAG
Diabetes Key Message Updates and comparison tables	<ul style="list-style-type: none"> • Blood Glucose Test Strips, Lancets and Pen Needles

NICE Guidance – acknowledged by the TAG

NG101 – July 2018, updated January 2024 - Early and locally advanced breast cancer: diagnosis and management
NG191 – March 2021, updated January 2024 - COVID-19 rapid guideline: managing COVID-19
NG188 – December 2020, updated January 2024 - COVID-19 rapid guideline: managing the long-term effects of COVID-19
NG192 – March 2021, updated January 2024 - Caesarean birth
NG51 – July 2016, updated January 2024 - Suspected sepsis: recognition, diagnosis, early management

NICE Technology Appraisals – NHS England Commissioning Responsibility

TA944 – Jan 2024 - Durvalumab (Imfinzi®) with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer	<p>RED/HOSPITAL - Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care</p>
TA946 – January 2024 - Olaparib (Lynparza®) with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer	
TA947 – January 2024 - Loncastuximab tesirine (Zynlonta®) for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments	
TA948 – January 2024 - Ivosidenib (Tibsovo®) for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments	

NICE Technology Appraisals – Terminated Appraisals

TA945 – January 2024 - Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases	<p>BLACK - Not commissioned. No NHS prescribing in primary or secondary care. Not recommended by NICE</p>
---	--

NICE NHS England Highly Specialised Technologies

HST30 – January 2024 - Sebelipase alfa (Kanuma®) for treating Wolman disease	<p>Red/Hospital - Prescribing to remain with the hospital or specialist service. No prescribing in primary care</p>
--	--

Useful Information

Next meeting	Wednesday 1st May 2024
Deadline for agenda submissions	Tuesday 23rd April 2024